| Literature DB >> 34193224 |
Huaiwu He1, Yi Chi1, Yingying Yang1, Siyi Yuan1, Yun Long2, Pengyu Zhao3, Inéz Frerichs4, Feng Fu5, Knut Möller6, Zhanqi Zhao7,8.
Abstract
BACKGROUND: Individualized positive end-expiratory pressure (PEEP) by electrical impedance tomography (EIT) has potential interest in the optimization of ventilation distribution in acute respiratory distress syndrome (ARDS). The aim of the study was to determine whether early individualized titration of PEEP with EIT improved outcomes in patients with ARDS.Entities:
Keywords: ARDS; Electrical impedance tomography; Organ function; PEEP titration
Year: 2021 PMID: 34193224 PMCID: PMC8243615 DOI: 10.1186/s13054-021-03645-y
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Fig. 1Individualized positive end-expiratory airway pressure titration using electrical impedance tomography in one patient of the EIT group. Optimal PEEP is defined the intercept point of cumulated collapse and overdistension percentage curves, providing the best compromise between collapsed and overdistended lung. If the intercept point occurred between two PEEP steps, the selected PEEP corresponded to the PEEP step toward the lowest global inhomogeneity index. For the presented example, selected PEEP is 6cmH2O
Fig. 2Flowchart of the enrolled patients. pts, patients
Baseline clinical characteristics and demographics of patients
| Variables | EIT group ( | Control group ( | |
|---|---|---|---|
| Age (years) | 61.0 (44.0, 68.0) | 66.5 (50.0, 73.0) | 0.074 |
| Female Sex | 19/61 | 21/56 | 0.597 |
| Body mass index (kg/m2) | 26.0 (22.9, 29.1) | 26.0 (22.9, 28.6) | 0.933 |
| APACHE II score | 19.0 (15.0, 25.0) | 18.0 (15.0, 21.2) | 0.568 |
| Reason for ARDS | |||
| Pneumonia | 28/61 | 24/56 | 0.884 |
| Extrapulmonary sepsis | 10/61 | 15/56 | 0.252 |
| Severe acute pancreatitis | 0/61 | 1/56 | 0.972 |
| Post-cardiac operation | 14/61 | 8/56 | 0.231 |
| Others | 9/61 | 8/56 | 0.848 |
| Mild ARDS | 18/61 | 23/56 | 0.292 |
| Moderate ARDS | 28/61 | 25/56 | 0.960 |
| Severe ARDS | 15/61 | 8/56 | 0.161 |
| Other parameters | |||
| Heart rate | 98.0 (86.0, 113.0) | 103.0 (88.2, 120.8) | 0.287 |
| Mean arterial pressure | 82.0 (73.0, 94.0) | 87.5 (75.8, 99.2) | 0.242 |
| Received NE ( | 53/61 (86.9%) | 53/56 (94.6%) | 0.151 |
| NE dose (ug/kg/min) | 0.1 (0.0, 0.3) | 0.1 (0.1, 0.2) | 0.715 |
| ScvO2 (%) | 73.7 (71.0, 81.7) | 76.2 (68.7, 81.6) | 0.953 |
| Pv-a CO2 (mmHg) | 4.6 (2.6, 6.6) | 4.3 (2.4, 7.0) | 0.923 |
| Arterial lactate (mmol/L) | 2.2 (1.4, 4.7) | 2.0 (1.4, 4.0) | 0.550 |
| White blood cell (10^9/L) | 9.8 (8.6, 11.3) | 10.3 (8.8, 12.8) | 0.287 |
ARDS, acute respiratory distress syndrome; NE, norepinephrine; ScvO2, central venous oxygen saturation; Pv-a CO2, venous-to-arterial carbon dioxide difference; APACHE II, Acute Physiology and Chronic Health Evaluation
Difference in respiratory and hemodynamic variables between groups
| Parameters | Day 0 | Day 1 | Day 2 | Day 3 | Trend |
|---|---|---|---|---|---|
| VT (ml) of PC mode | |||||
| EIT group | 414 (383, 460) | 450 (390, 520) * | 430(373, 490) | 429 (364, 497) | 0.306 |
| Control group | 407 (362, 463) | 410(370, 445) | 411(370, 481) | 426 (345, 485) | 0.153 |
| Driving pressure (cmH2O) | |||||
| EIT group | 14(11, 15) | 13(11, 15) | 13(11, 15) | 13 (11, 15) | 0.631 |
| Control group | 13 (11, 15) | 13 (12, 14) | 12(11.0, 15) | 13 (10, 15) | 0.772 |
| Pmean (cmH2O) | |||||
| EIT group | 10 (9, 12) | 12 (10, 14) | 12 (10, 14) | 12 (10, 14) | 0.065 |
| Control group | 10 (9, 12) | 11 (10, 13) | 12 (9, 13) | 11 (10, 13) | 0.445 |
| RR (bpm) | |||||
| EIT group | 15 (15, 15) | 15(14, 18) | 16(15, 20) | 18 (14, 22) | < 0.0001 |
| Control group | 15 (15, 16) | 16(15, 18) | 15(15, 18) | 17 (14, 20) | < 0.0001 |
| Respiratory compliance (ml/cmH2O) | |||||
| EIT group | 32 (27, 41) | 33 (25, 43) | 31 (25, 38) | 33 (25, 43) | 0.239 |
| Control group | 30 (24, 37) | 30 (24, 37) | 30 (24, 40) | 33 (24, 43) | 0.150 |
| PEEP (cmH2O) | |||||
| EIT group | 8 (6, 9) | 8 (6, 9) | 8 (6,9) | 8 (6, 9) | 0.287 |
Control group pH | 8 (5, 10) | 8 (6, 9) | 8 (6, 9) | 7 (6, 9) | 0.249 |
| EIT group | 7.4 (7.3, 7.4) | 7.4 (7.4, 7.5) | 7.4 (7.4, 7.5) | 7.4 (7.4, 7.5) | < 0.0001 |
| Control group | 7.4 (7.3, 7.4) | 7.4 (7.4, 7.5) | 7.5 (7.4, 7.5) | 7.5 (7.4, 7.5) | < 0.0001 |
| PaCO2 (mmHg) | |||||
| EIT group | 39 (36, 46) | 39 (38, 43) | 42 (39, 46) | 41 (38, 44) | 0.239 |
| Control group | 40 (35, 43) | 41(39, 44) | 39 (37, 43) | 40 (38, 43) | 0.817 |
| PaO2 (mmHg) | |||||
| EIT group | 82 (74, 96) | 92 (76, 104) | 91 (79, 110) | 96 (79, 118) | 0.183 |
| Control group | 88 (70, 122) | 93 (79, 111) | 96 (74, 114) | 95 (78, 116) | 0.984 |
| PaO2/FiO2 (mmHg) | |||||
| EIT group | 165 (106, 213) | 187 (144, 242) | 214 (165, 283) | 220 (170, 295) | < 0.0001 |
| Control group | 176 (139, 222) | 212 (170, 269) | 232 (155, 316) | 231 (180, 295) | 0.001 |
| Lactate (mmol/L) | |||||
| EIT group | 2.2 (1.4, 4.7) | 1.9 (1.2, 2.9) | 1.2 (1.0, 2.0) | 1.3 (0.9, 1.6) | < 0.0001 |
| Control group | 2.0 (1.4, 4.0) | 2.0 (1.2, 2.8) | 1.6 (1.1, 2.1) | 1.4 (1.1, 1.8) | < 0.0001 |
| APACHE II | |||||
| EIT group | 19 (14,25) | 18 (12, 24) | 15 (12, 21) | 16 (12, 19) | < 0.0001 |
| Control group | 17 (14,20) | 18 (16, 21) | 16 (13, 21) | 15 (13, 20) | < 0.0001 |
| SOFA | |||||
| EIT group | 13 (11, 14) | 12 (10, 14) | 11 (9, 13) | 11 (9,13) | < 0.0001 |
| Control group | 12 (9, 13) | 12 (11, 14) | 12 (10, 14) | 12 (10,14) | 0.022 |
*EIT group versus control group, p < 0.05. VT, tidal volume; PC, pressure control mode; Pmean, mean airway pressure; RR, respiratory rate; PEEP, positive end-expiratory pressure; APACHE II, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment
Fig. 3Distribution of the difference values and agreement of Bland–Altman plot between PEEPeit and PEEPlower table methods in the EIT group. Out of 61 patients, 41 exhibited an absolute difference value between PEEPeit and PEEPlower table ≥ 2cmH2O. Mean difference between the PEEPeit and PEEPlower table was − 0.1 [95% limits of agreement was from 6.4 to (− 6.6) cmH2O]
Main outcome variables and adjuvant therapies in the two study groups
| Variables | EIT group | Control group | |
|---|---|---|---|
| Clinical outcome | |||
| 28-day mortality ( | 13 (21%) | 15 (27%) | 0. 634 |
| Ventilator-free days at day 28 (D) | 14.0 (0.0, 23.0) | 18.5 (0.0, 24.0) | 0.764 |
| Length of ICU stay (D) | 13.0 (7.0, 25.0) | 10.0 (7.0, 14.8) | 0.169 |
| ΔD1 SOFA score | 0 (− 1, 1) | 0.5 (− 1, 2.75) | 0.021* |
| ΔD2 SOFA score | − 1 (− 3.5, 0) | 1 (− 2, 2) | < 0.0001* |
| Successful extubation ( | 30 (49%) | 31 (55%) | 0.629 |
| Tracheostomy ( | 17 (28%) | 11 (20%) | 0.409 |
| Adjuvant therapy | |||
| Neuromuscular blocker ( | 12 (20%) | 5 (9%) | 0.166 |
| Prone position ( | 30 (49%) | 23 (41%) | 0.487 |
| Glucocorticoid therapy ( | 11 (18%) | 6 (11%) | 0.390 |
*p < 0.05
Fig. 4Kaplan–Meier 28-day probability of survival curve for the EIT group and the control group